BioCentury
ARTICLE | Company News

Alexion shuffles management again

May 23, 2017 6:59 PM UTC

Rare disease company Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said a handful of key executives are leaving the company. Among them are Chief Commercial Officer Carsten Thiel, CFO Dave Anderson and EVP and Head of R&D Martin Mackay.

Brian Goff is to replace Thiel, effective June 1. Goff was COO at Neurovance Inc., which Otsuka Pharmaceutical Co. Ltd. (Tokyo:4578) acquired this year. Prior to joining Neurovance, Goff was EVP and president of hematology at Baxalta Inc., which Shire plc (LSE:SHP; NASDAQ:SHPG) acquired. Alexion CEO Ludwig Hantson was Baxalta's president and CEO (see BioCentury Extra, March 27)...

BCIQ Company Profiles

Alexion Pharmaceuticals Inc.